Shiqi Diao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shiqi Diao has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Antonis E. Koromilas
McGill University
2 shared publications Hyungdong Kim
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital, Montreal, Canada
2 shared publications- Shuo Wang
Lady Davis Institute for Medical Research, McGill University, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada
2 shared publications Constantinos Koumenis
Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, USA
1 shared publication- Gerard I. Evan
The Francis Crick Institute, London, UK
1 shared publication - Jason E. Chan
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA
1 shared publication
Latest Publications
- Open Access
- 15 June 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (7) , 1-16
Integrated stress response couples mitochondrial fitness with lineage reprogramming to drive cancer evolution
Tumour progression towards dedifferentiated cell clusters plays a critical role in intratumour heterogeneity and therapy resistance. While tumour microenvironmental stress has been implicated, the underlying mechanisms remain poorly defined. Using mouse models of lung adenocarcinoma, we demonstrate that activation of the integrated stress response (ISR)—marked by phosphorylation of eIF2 (p-eIF2) and ATF4 induction—drives tumour heterogeneity. ISR activation facilitates the emergence of high-plasticity, undifferentiated and pre-epithelial-to-mesenchymal transition clusters characterized by elevated ATF4 and MYC activity. This process is MYC dependent and involves ISR-mediated repression of NKX2-1, a key determinant of alveolar identity, and induction of CHCHD10, a regulator of mitochondrial integrity and metabolic fitness. Disruption of the p-eIF2–ATF4 axis induces mitochondrial dysfunction, limits dedifferentiation and suppresses tumour growth. In human lung adenocarcinoma, ISR-driven dedifferentiation correlates with advanced disease and poor prognosis, identifying the ISR as a central driver of lineage reprogramming and metabolic fitness in tumour progression.
- 15 June 2026
- Published by Springer Nature in Nature Cell Biology
- Vol. 28 (7) , 1-16
Open AccessIntegrated stress response couples mitochondrial fitness with lineage reprogramming to drive cancer evolution
Tumour progression towards dedifferentiated cell clusters plays a critical role in intratumour heterogeneity and therapy resistance. While tumour microenvironmental stress has been implicated, the underlying mechanisms remain poorly defined. Using mouse models of lung adenocarcinoma, we demonstrate that activation of the integrated stress response (ISR)—marked by phosphorylation of eIF2 (p-eIF2) and ATF4 induction—drives tumour heterogeneity. ISR activation facilitates the emergence of high-plasticity, undifferentiated and pre-epithelial-to-mesenchymal transition clusters characterized by elevated ATF4 and MYC activity. This process is MYC dependent and involves ISR-mediated repression of NKX2-1, a key determinant of alveolar identity, and induction of CHCHD10, a regulator of mitochondrial integrity and metabolic fitness. Disruption of the p-eIF2–ATF4 axis induces mitochondrial dysfunction, limits dedifferentiation and suppresses tumour growth. In human lung adenocarcinoma, ISR-driven dedifferentiation correlates with advanced disease and poor prognosis, identifying the ISR as a central driver of lineage reprogramming and metabolic fitness in tumour progression.
- Open Access
- 25 August 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-16
A feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer
In tumorous conditions, STAT1, traditionally recognized for its anti-tumor role in immunology, exhibits pro-survival characteristics, though unclear mechanisms. Investigating STAT1 function in isogenic colorectal tumor cells with wild-type or mutant KRAS, we found that STAT1 specifically promotes tumor survival and proliferation with mutant KRAS. Gene expression profiling revealed that STAT1 promotes the expression of sterol and lipid biosynthesis genes in these cells. This effect depends on STAT1 phosphorylation at S727, which upregulates SREBP1 and SREBP2 to drive de novo lipid production. In mutant KRAS cells, STAT1 amplifies the mevalonate pathway, maintaining its S727 phosphorylation and establishing a positive feedback loop through the transcription factors YAP1 and TEAD4, further driving lipid biosynthesis and tumor growth. This STAT1-YAP1 axis promotes mutant KRAS tumor cells’ resistance to mevalonate pathway inhibitors, which can be overcome by pharmacologically targeting the YAP1-TEAD interaction. Moreover, this axis contributes to the inherent resistance of mutant KRAS colon cancer cells to EGFR-targeted therapy. Together, these findings identify the STAT1-YAP1 pathway as a critical mediator of therapy resistance and a promising therapeutic target in mutant KRAS colorectal cancer.
- 25 August 2025
- Published by Springer Nature in Communications Biology
- Vol. 8 (1) , 1-16
Open AccessA feedforward loop between STAT1 and YAP1 stimulates lipid biosynthesis, accelerates tumor growth, and promotes chemotherapy resistance in mutant KRAS colorectal cancer
In tumorous conditions, STAT1, traditionally recognized for its anti-tumor role in immunology, exhibits pro-survival characteristics, though unclear mechanisms. Investigating STAT1 function in isogenic colorectal tumor cells with wild-type or mutant KRAS, we found that STAT1 specifically promotes tumor survival and proliferation with mutant KRAS. Gene expression profiling revealed that STAT1 promotes the expression of sterol and lipid biosynthesis genes in these cells. This effect depends on STAT1 phosphorylation at S727, which upregulates SREBP1 and SREBP2 to drive de novo lipid production. In mutant KRAS cells, STAT1 amplifies the mevalonate pathway, maintaining its S727 phosphorylation and establishing a positive feedback loop through the transcription factors YAP1 and TEAD4, further driving lipid biosynthesis and tumor growth. This STAT1-YAP1 axis promotes mutant KRAS tumor cells’ resistance to mevalonate pathway inhibitors, which can be overcome by pharmacologically targeting the YAP1-TEAD interaction. Moreover, this axis contributes to the inherent resistance of mutant KRAS colon cancer cells to EGFR-targeted therapy. Together, these findings identify the STAT1-YAP1 pathway as a critical mediator of therapy resistance and a promising therapeutic target in mutant KRAS colorectal cancer.